Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Current Assets (2019 - 2026)

ADC Therapeutics has reported Current Assets over the past 8 years, most recently at $276.8 million for Q1 2026.

  • Quarterly results put Current Assets at $276.8 million for Q1 2026, up 7.28% from a year ago — trailing twelve months through Mar 2026 was $276.8 million (up 7.28% YoY), and the annual figure for FY2025 was $306.3 million, up 5.18%.
  • Current Assets reached $276.8 million in Q1 2026 per ADCT's latest filing, down from $306.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $487.7 million in Q1 2022 and bottomed at $258.0 million in Q1 2025.
  • Median Current Assets over the past 5 years was $336.3 million (2023), compared with a mean of $349.9 million.
  • The largest annual shift saw Current Assets grew 24.02% in 2022 before it fell 23.63% in 2024.
  • Over 5 years, Current Assets stood at $376.5 million in 2022, then dropped by 10.67% to $336.3 million in 2023, then fell by 13.39% to $291.3 million in 2024, then grew by 5.18% to $306.3 million in 2025, then fell by 9.65% to $276.8 million in 2026.
  • Business Quant data shows Current Assets for ADCT at $276.8 million in Q1 2026, $306.3 million in Q4 2025, and $287.1 million in Q3 2025.